Is Longeveron, Inc. overvalued or undervalued?

As of 14 August 2024, the valuation grade for Longeveron, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.08, an EV to Sales ratio of 2.14, and a troubling ROCE of -508.69%. In comparison to its peers, Surrozen, Inc. has a P/E ratio of 7.84, while GeoVax Labs, Inc. shows a less negative EV to EBITDA of -0.5852, highlighting Longeveron's relative weakness in the market.
The stock has performed poorly against the S&P 500, with a year-to-date return of -55.49% compared to the index's gain of 12.22%. This stark contrast reinforces the notion that Longeveron is not only struggling financially but also failing to deliver value to its investors.